Literature DB >> 22741748

Quality of life in patients with overactive bladder: validation and psychometric properties of the Spanish Overactive Bladder Questionnaire-short Form.

Salvador Arlandis1, Miguel A Ruiz, Carlos Errando, Felipe Villacampa, Daniel Arumí, Isabel Lizarraga, Javier Rejas.   

Abstract

BACKGROUND: Overactive bladder (OAB) is characterized by the symptoms of urinary urgency or urge incontinence, which appear without a local pathological or metabolic explanation. OAB is defined by symptoms and the evaluation of treatment effectiveness should be based upon patient perceptions. The Overactive Bladder Questionnaire-Short Form (OAB-q SF) is a brief, self-administered patient-reported outcomes tool with two scales assessing symptom bother and health-related quality of life (HR-QOL) in patients with OAB.
OBJECTIVE: This study aimed to adapt the OAB-q SF into Spanish and to estimate its psychometric properties in patients with symptomatic overactive bladder.
METHODS: The Spanish version of the OAB-q SF was administered on two occasions, 3 months apart, to a set of patients of both sexes, over 18 years of age, diagnosed with OAB, scoring ≥8 on the OAB-V8 scale (a self-reported 8-item OAB screening and awareness tool), and able to understand patient-reported-outcome instruments written in Spanish. Patients were recruited consecutively at urology clinics. Feasibility, internal consistency (Cronbach's alpha), test-retest reliability, structure of instrument, criteria and construct validity and responsiveness were examined using classic test theory statistics.
RESULTS: Data from 246 OAB patients (mean age 57.7 years, 76% women, 99% Caucasian, 37% workers and 36% with a primary education) were evaluated. Floor and ceiling effects ranged between 0.8% and 33%, and missing items were below 2%. Cronbach's alphas attained 0.811 and 0.922 for symptom-bother and HR-QOL domains, respectively. These two subscales matched the original structure and explained variances above 50%, which correlated moderately with EQ-5D (EuroQol) [r = -0.28 and r = +0.31, respectively (p < 0.001 in both cases)]. A significant change in OAB-q SF mean domain scores (-23.8; 95% CI -26.3, -21.3; and +17.7; 95% CI 15.4, 20.6; p < 0.001 in both cases; [effect sizes: 1.32 and 0.98]) was observed after 3 months of medical treatment.
CONCLUSION: The Spanish version of the OAB-q SF demonstrated sufficiently strong psychometric properties of reliability, validity and responsiveness to be used in the measurement of OAB symptom severity and HR-QOL.

Entities:  

Mesh:

Year:  2012        PMID: 22741748     DOI: 10.2165/11633760-000000000-00000

Source DB:  PubMed          Journal:  Clin Drug Investig        ISSN: 1173-2563            Impact factor:   2.859


  24 in total

1.  The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society.

Authors:  Paul Abrams; Linda Cardozo; Magnus Fall; Derek Griffiths; Peter Rosier; Ulf Ulmsten; Philip van Kerrebroeck; Arne Victor; Alan Wein
Journal:  Neurourol Urodyn       Date:  2002       Impact factor: 2.696

2.  EuroQol--a new facility for the measurement of health-related quality of life.

Authors: 
Journal:  Health Policy       Date:  1990-12       Impact factor: 2.980

3.  Determining the importance of change in the overactive bladder questionnaire.

Authors:  Karin S Coyne; Louis S Matza; Christine L Thompson; Zoe S Kopp; Vikram Khullar
Journal:  J Urol       Date:  2006-08       Impact factor: 7.450

Review 4.  Psychometric considerations in evaluating health-related quality of life measures.

Authors:  R D Hays; R Anderson; D Revicki
Journal:  Qual Life Res       Date:  1993-12       Impact factor: 4.147

Review 5.  Cross-cultural adaptation of health-related quality of life measures: literature review and proposed guidelines.

Authors:  F Guillemin; C Bombardier; D Beaton
Journal:  J Clin Epidemiol       Date:  1993-12       Impact factor: 6.437

6.  Multilingual translation of the Functional Assessment of Cancer Therapy (FACT) quality of life measurement system.

Authors:  A E Bonomi; D F Cella; E A Hahn; K Bjordal; B Sperner-Unterweger; L Gangeri; B Bergman; J Willems-Groot; P Hanquet; R Zittoun
Journal:  Qual Life Res       Date:  1996-06       Impact factor: 4.147

7.  The impact of overactive bladder on mental health, work productivity and health-related quality of life in the UK and Sweden: results from EpiLUTS.

Authors:  Karin S Coyne; Chris C Sexton; Zoe S Kopp; Caty Ebel-Bitoun; Ian Milsom; Chris Chapple
Journal:  BJU Int       Date:  2011-03-03       Impact factor: 5.588

8.  The impact of overactive bladder, incontinence and other lower urinary tract symptoms on quality of life, work productivity, sexuality and emotional well-being in men and women: results from the EPIC study.

Authors:  Karin S Coyne; Chris C Sexton; Debra E Irwin; Zoe S Kopp; Con J Kelleher; Ian Milsom
Journal:  BJU Int       Date:  2008-06       Impact factor: 5.588

9.  Psychometric validation of an overactive bladder symptom and health-related quality of life questionnaire: the OAB-q.

Authors:  K Coyne; D Revicki; T Hunt; R Corey; W Stewart; J Bentkover; H Kurth; P Abrams
Journal:  Qual Life Res       Date:  2002-09       Impact factor: 4.147

10.  Prevalence and burden of overactive bladder in the United States.

Authors:  W F Stewart; J B Van Rooyen; G W Cundiff; P Abrams; A R Herzog; R Corey; T L Hunt; A J Wein
Journal:  World J Urol       Date:  2002-11-15       Impact factor: 4.226

View more
  4 in total

1.  Mapping of the OAB-SF Questionnaire onto EQ-5D in Spanish Patients with Overactive Bladder.

Authors:  Miguel A Ruiz; Laura L Gutiérrez; Manuel Monroy; Javier Rejas
Journal:  Clin Drug Investig       Date:  2016-04       Impact factor: 2.859

2.  Predicting self-perceived antimuscarinic therapy effectiveness on overactive bladder symptoms using the Overactive Bladder 8-Question Awareness Tool.

Authors:  Felipe Villacampa; Miguel A Ruiz; Carlos Errando; Salvador Arlandis; Daniel Arumí; Isabel Lizarraga; Javier Rejas
Journal:  Int Urogynecol J       Date:  2012-10-31       Impact factor: 2.894

3.  Cost-effectiveness analysis of fesoterodine flexible dose in newly diagnosed patients with overactive bladder in routine clinical practice in Spain.

Authors:  Carmen Peral; Francisco Sánchez-Ballester; José M García-Mediero; Jaime Ramos; Javier Rejas
Journal:  Clinicoecon Outcomes Res       Date:  2016-09-26

4.  Laparoscopic Abdominopexy: Surgery for Vaginal Prolapse.

Authors:  Rodrigo Gil Ugarteburu; Laura Rúger Jiménez; Luis Rodríguez Villamil; Rebeca Blanco Fernández; Iván González Rodríguez; Guillermo Cruceyra Betriú; Jose Manuel Pello Fonseca; Javier Mosquera Madera
Journal:  JSLS       Date:  2019 Apr-Jun       Impact factor: 2.172

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.